25 Oct 2025 Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets Investors | Therapeutics
21 Oct 2025 ESMO Phase 1a data for faridoxorubicin presented by Chris Coughlin and David Liebowitz Therapeutics
19 Oct 2025 Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION® platform at the European Society of Medical Oncology Annual Congress Therapeutics
13 Oct 2025 Research & Development Spotlight Series, Episode 12 Investors | R&D Spotlights Series | Therapeutics
13 Oct 2025 Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium Therapeutics
09 Sep 2025 Avacta’s pre|CISION® Platform Shortlisted for the Technology of the Year Award at the AIM Awards Investors | Therapeutics
29 Aug 2025 Amendments to the Convertible Bond and equity fundraise of £3.25 million Investors | Therapeutics
30 Jul 2025 Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress Therapeutics